- cafead   Jul 18, 2023 at 10:42: AM
via From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular disease—Argenx’s flagship drug Vyvgart is proving its merit as a potential franchise.
article source
article source